{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:08:52Z","timestamp":1772820532060,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.cllc.2018.12.020","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T19:21:09Z","timestamp":1546284069000},"page":"215-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Lorlatinib in Korean Non\u2013Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0374-3240","authenticated-orcid":false,"given":"Jiyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.12.020_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non\u2013small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.cllc.2018.12.020_bib2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and outcome of ROS1-positive non\u2013small cell lung cancer patients in routine clinical practice","volume":"13","author":"Park","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib4","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0b013e31826baf83","article-title":"Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non\u2013small-cell lung cancer","volume":"7","author":"Chin","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non\u2013small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2018.12.020_bib6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2018.12.020_bib7","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.12.020_bib8","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non\u2013small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.12.020_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort","volume":"33","author":"Mazieres","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non\u2013small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non\u2013small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.12.020_bib12","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib13","unstructured":"Gainor JF, Tseng D, Yoda S, et\u00a0al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non\u2013small-cell lung cancer. JCO Precis Oncol. In press."},{"key":"10.1016\/j.cllc.2018.12.020_bib14","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non\u2013small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.12.020_bib15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2018.12.020_bib16","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non\u2013small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib17","doi-asserted-by":"crossref","first-page":"S1756","DOI":"10.1016\/j.jtho.2017.09.351","article-title":"Phase 2 study of lorlatinib in patients with advanced ALK+\/ROS1+ non\u2013small-cell lung cancer (abstract OA 05.06)","volume":"12","author":"Solomon","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2018.12.020_bib19","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2018.12.020_bib20","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent advances in targeting ROS1 in lung cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib21","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41467-017-01470-y","article-title":"Prevalence and detection of low-allele-fraction variants in clinical cancer samples","volume":"8","author":"Shin","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2018.12.020_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2018.12.020_bib23","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cllc.2018.12.020_bib24","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1111\/ajco.12645","article-title":"Characteristics and outcomes of ALK+ non\u2013small cell lung cancer patients in Korea","volume":"13","author":"Lim","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib25","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.12.020_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2018.12.020_bib27","first-page":"1173","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"369","author":"Awad","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.12.020_bib28","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-14-1350","article-title":"Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non\u2013small cell lung cancer","volume":"21","author":"Song","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.12.020_bib29","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-13-A277","article-title":"PF-06463922, a novel ROS1\/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models","volume":"12","author":"Zou","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2018.12.020_bib30","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.12.020_bib31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1078-0432.CCR-15-1601","article-title":"Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer","volume":"23","author":"Chong","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418303577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418303577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:27Z","timestamp":1761505707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418303577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1525730418303577"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.12.020","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Lorlatinib in Korean Non\u2013Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}